{
  "schemaVersion": 1,
  "id": "research-059",
  "slug": "059-how-redefine-1-researchers-studied-blood-pressure",
  "title": "How REDEFINE 1 researchers studied blood pressure",
  "catalogLabel": "Cagrilintide",
  "productCollection": "https://heritagebiolabs.com/research-library/products/cagrilintide",
  "productHandles": [
    "cagrilintide-701"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/cagrilintide-701"
  ],
  "readingFocus": "Mechanisms & biology",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 403,
  "sourceYears": [
    2023,
    2025,
    2026
  ],
  "paragraphs": [
    "A peptide is a short chain of amino acids connected by peptide bonds. Some peptides activate receptors that help regulate appetite and metabolism. Cagrilintide is an investigational amylin-based peptide studied alone and as part of CagriSema with semaglutide. An analysis published in December 2025 examined blood pressure readings collected in the REDEFINE 1 weight-management trial. The authors wanted to know whether pressure changes differed between the combination and placebo groups. [1]",
    "Blood pressure is written as two numbers. Systolic pressure is the first number and reflects pressure while the heart contracts. Diastolic pressure is the second number and reflects pressure between contractions. At week 68, the average systolic pressure had declined by 10.9 mm Hg in the CagriSema group and by 2.8 mm Hg in the placebo group. Average diastolic declines were 5.4 and 1.7 mm Hg, respectively. These results were collected in adults with overweight or obesity without diabetes who also received lifestyle support. [1]",
    "The investigators looked at changes in blood pressure medicines and at smaller groups defined by participants’ starting characteristics. Among participants with resistant hypertension at baseline, the proportion reaching the specified pressure target was numerically higher with CagriSema. The uncertainty interval for the comparison was wide and included the possibility of no difference. Estimates from a smaller subgroup can be less precise because the calculation rests on fewer participants. [1]",
    "Some of the paper’s analyses were secondary to the original weight question and some were conducted after the main trial data were available. These analyses help investigators identify patterns and ask more specific questions. They can also contain more uncertainty than the primary outcome around which the trial was designed. In particular, the pressure finding belongs to the fixed combination. Although the trial included cagrilintide and semaglutide arms, the highlighted pressure estimates compare the combination with placebo. The comparison does not assign the full change to either peptide alone. [1, 2]",
    "Blood pressure readings can be measured repeatedly over a trial, so they are useful for evaluating a possible change in cardiovascular risk factors. Whether a treatment reduces events such as heart attacks or strokes requires counting those events in a study designed to address that question. REDEFINE 3 was registered to assess cardiovascular outcomes with CagriSema in a different population. Its registry listed no posted results by November 8, 2026. The completed blood pressure analysis and that trial’s plan answer different questions about cardiovascular evidence. [1, 3]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Subodh Verma et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension (publication 2025-12-02).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41328546/"
    },
    {
      "number": 2,
      "citation": "W. Timothy Garvey et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine (publication 2025-06-22).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40544433/"
    },
    {
      "number": 3,
      "citation": "Novo Nordisk A/S. REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels. ClinicalTrials.gov (publication 2023-01-03, record updated 2026-08-31).",
      "url": "https://clinicaltrials.gov/study/NCT05669755"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/059-how-redefine-1-researchers-studied-blood-pressure",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/059-how-redefine-1-researchers-studied-blood-pressure.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/059-how-redefine-1-researchers-studied-blood-pressure.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 012 - Cagrilintide.docx",
    "sourceArticleNumber": 59,
    "contentSha256": "84548597a88cc246e93b2160d9bf37c8a77119a075f29420264bafd7de1cb505",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
